Enoumena Therapeutics Inc. News Releases https://feeds.newsfilecorp.com/company/12791 Latest news from Enoumena Therapeutics Inc., as distributed by TMX Newsfile. en CopyRight (c) 2026, Newsfile Corp. All Rights Reserved. office@newsfilecorp.com (Newsfile Corp.) office@newsfilecorp.com (Newsfile Corp.) Thu, 08 Oct 2026 10:48:19 -0400 https://images.newsfilecorp.com/logos/12791.jpg Enoumena Therapeutics Inc. News Releases https://feeds.newsfilecorp.com/company/12791 Enoumena Therapeutics et AOP Health annoncent une entente exclusive de commercialisation au Canada de SIBBORAN(R) (landiolol) https://www.newsfilecorp.com/release/318090/Enoumena-Therapeutics-et-AOP-Health-annoncent-une-entente-exclusive-de-commercialisation-au-Canada-de-SIBBORANR-landiolol Montréal, Québec et Vienne, Autriche--(Newsfile Corp. - 8 octobre 2026) - Enoumena Therapeutics Inc. et AOP Health ont annoncé aujourd'hui la conclusion d'une entente exclusive de commercialisation visant à élargir l'accès des établissements de santé canadiens à PrSIBBORAN® (chlorhydrate de landiolol), un bêtabloquant sélectif des récepteurs bêta-1 adrénergiques à action ultra-courte.Autorisé par Santé Canada en 2023, SIBBORAN est indiqué pour la réduction à court terme de la fréquence...<img src="https://api.newsfilecorp.com/newsinfo/318090/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Thu, 08 Oct 2026 10:47:00 -0400 fr https://www.newsfilecorp.com/release/318090 Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol) https://www.newsfilecorp.com/release/318089/Enoumena-Therapeutics-and-AOP-Health-Announce-Exclusive-Canadian-Commercialization-Agreement-for-SIBBORANR-landiolol Montreal, Quebec and Vienna, Austria--(Newsfile Corp. - October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker.Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial...<img src="https://api.newsfilecorp.com/newsinfo/318089/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Thu, 08 Oct 2026 10:47:00 -0400 en https://www.newsfilecorp.com/release/318089